A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma

Because 18F-FDG PET has insufficient sensitivity for the detection of hepatocellular carcinoma (HCC), 11C-acetate PET has been proposed as another technique for this use. We prospectively evaluated the value of PET/CT using these 2 tracers for the detection of primary and metastatic HCC. Methods: One hundred twelve patients (99 with HCC, 13 with cholangiocellular carcinoma) underwent biopsy and 18F-FDG and 11C-acetate PET/CT. Results: The overall sensitivities of 18F-FDG, 11C-acetate, and dual-tracer PET/CT in the detection of 110 lesions in 90 patients with primary HCC were 60.9%, 75.4%, and 82.7%, respectively. Elevated serum α-fetoprotein levels, an advanced tumor stage, portal vein tumor thrombosis, large tumors, and multiple tumors were significantly associated with positive 18F-FDG PET/CT results. Uptake of 11C-acetate was associated with large and multiple tumors. For 18F-FDG, the sensitivities according to tumor size (1–2, 2–5, and ≥5 cm) were 27.2%, 47.8%, and 92.8%, respectively; for 11C-acetate, these respective values were 31.8%, 78.2%, and 95.2%. 18F-FDG was more sensitive in the detection of poorly differentiated HCC. Overall survival was lower in patients with 18F-FDG PET/CT positive for all indexed lesions than in those with FDG negative or partially positive through the entire follow-up period. In analysis based on biopsied lesions, the sensitivity of 18F-FDG PET/CT was 64.4% for primary HCC and 84.4% for 11C-acetate PET/CT. The overall sensitivities of 18F-FDG, 11C-acetate, and dual-tracer PET/CT for 35 metastatic HCCs were 85.7%, 77.0%, and 85.7%, respectively. There was no significant difference in the sensitivity of tracers according to metastatic tumor size, location, or differentiation. Conclusion: The addition of 11C-acetate to 18F-FDG PET/CT increases the overall sensitivity for the detection of primary HCC but not for the detection of extrahepatic metastases. 18F-FDG, 11C-acetate, and dual-tracer PET/CT have a low sensitivity for the detection of small primary HCC, but 18F-FDG PET/CT has a relatively high sensitivity for the detection of extrahepatic metastases of HCC.

[1]  M. Laeeq Khan,et al.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. , 2000, Journal of hepatology.

[2]  W. Chapman,et al.  The Role of [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging in the Evaluation of Hepatocellular Carcinoma , 2003, The American surgeon.

[3]  I. Wanless,et al.  Terminology of nodular hepatocellular lesions , 1995 .

[4]  Joong-Won Park,et al.  Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area , 2007, Journal of Cancer Research and Clinical Oncology.

[5]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  S. Zeuzem,et al.  Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma , 1999, American Journal of Gastroenterology.

[7]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[8]  Joong-Won Park.  [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. , 2004, The Korean journal of hepatology.

[9]  C. Bai,et al.  Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. , 2005, Anticancer research.

[10]  Byung Tae Kim,et al.  Relationship between Gastrointestinal F-18-fluorodeoxyglucose Accumulation and Gastrointestinal Symptoms in Whole-Body PET. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[11]  J. Geoghegan,et al.  Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors , 2004, Journal of Cancer Research and Clinical Oncology.

[12]  A. Tamori,et al.  Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma , 2001, American Journal of Gastroenterology.

[13]  Y. Cho,et al.  The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  T. Saga,et al.  Preoperative Positron Emission Tomography with Fluorine-18-Fluorodeoxyglucose is Predictive of Prognosis in Patients with Hepatocellular Carcinoma after Resection , 2006, World Journal of Surgery.

[15]  K. Iwaisako,et al.  Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma , 2007, Clinical Cancer Research.

[16]  Tae Hyun Kim,et al.  Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus–endemic area , 2008, Journal of gastroenterology and hepatology.

[17]  Y. Cho,et al.  The role of 18F‐FDG‐PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients , 2006 .

[18]  Toshihiko Kanno,et al.  18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma , 2004, Journal of Gastroenterology.

[19]  Chi-Lai Ho,et al.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  K. Togashi,et al.  Diagnostic accuracy of bone metastases detection in cancer patients: Comparison between bone scintigraphy and whole-body FDG-PET , 2006, Annals of nuclear medicine.

[21]  C. Crouzel,et al.  An improvement of 11C acetate synthesis--non-radioactive contaminants by irradiation-induced species emanating from the 11C carbon dioxide production target. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[22]  Joong-Won Park,et al.  [Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma]. , 2006, The Korean journal of hepatology.

[23]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[24]  H. Koga,et al.  Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[25]  S. Seki,et al.  Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors , 2000, Annals of nuclear medicine.

[26]  R. Valkema,et al.  Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. , 2002, Liver.

[27]  Sirong Chen,et al.  Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma , 2007, Journal of Nuclear Medicine.

[28]  O. Nakashima,et al.  Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. , 1994, Japanese journal of clinical oncology.

[29]  Michael J. Morris,et al.  11C-acetate PET imaging in prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  P Neuhaus,et al.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis , 2001, Hepatology.

[31]  Y. Guan,et al.  Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. , 2007, World journal of gastroenterology.